DDInter814 DDInter624
Gemtuzumab ozogamicin is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp. calichensis. Gemtuzumab ozogamicin has approximately 50% of the antibody loaded with 4-6 moles calicheamicin per mole of antibody [FDA Label]. The antibody is specifically directed against the CD33 antigen present on leukemic myeloblasts in most patients with acute myeloid leukemia (AML). By binding to the CD33 antigen on tumors, the cytotoxic agent blocks the growth of cancerous cells and causes cell death. Marketing approval of gemtuzumab ozogamicin was granted on May 17, 2000 by FDA as a treatment for patients with CD33-positive AML in first relapse who are 60 years of age or
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
Gemtuzumab ozogamicin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Moxifloxacin
Moxifloxacin {u} (Compound) causes {v} (Side Effect) Connective tissue disorder
Connective tissue disorder {u} (Side Effect) is caused by {v} (Compound) Efavirenz
Gemtuzumab ozogamicin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ofloxacin
Ofloxacin {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Efavirenz
Gemtuzumab ozogamicin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Gatifloxacin
Gatifloxacin {u} (Compound) upregulates {v} (Gene) IKBKB
IKBKB {u} (Gene) is upregulated by {v} (Compound) Efavirenz
Gemtuzumab ozogamicin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Gatifloxacin
Gatifloxacin {u} (Compound) downregulates {v} (Gene) OXA1L
OXA1L {u} (Gene) is downregulated by {v} (Compound) Efavirenz
Gemtuzumab ozogamicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Topotecan
Topotecan {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Efavirenz
Gemtuzumab ozogamicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epirubicin
Epirubicin {u} (Compound) upregulates {v} (Gene) IKBKB
IKBKB {u} (Gene) is upregulated by {v} (Compound) Efavirenz
Gemtuzumab ozogamicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Topotecan
Topotecan {u} (Compound) downregulates {v} (Gene) OXA1L
OXA1L {u} (Gene) is downregulated by {v} (Compound) Efavirenz
Gemtuzumab ozogamicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ganciclovir
Ganciclovir {u} (Compound) causes {v} (Side Effect) Creatinine increased
Creatinine increased {u} (Side Effect) is caused by {v} (Compound) Efavirenz
Gemtuzumab ozogamicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methotrexate
Methotrexate {u} (Compound) upregulates {v} (Gene) OXA1L
OXA1L {u} (Gene) is downregulated by {v} (Compound) Efavirenz
Gemtuzumab ozogamicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zidovudine
Zidovudine {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) is treated by {v} (Compound) Efavirenz
Gemtuzumab ozogamicin may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin and Moxifloxacin (Compound) causes Connective tissue disorder (Side Effect) and Connective tissue disorder (Side Effect) is caused by Efavirenz (Compound)
Gemtuzumab ozogamicin may cause a minor interaction that can limit clinical effects when taken with Ofloxacin and Ofloxacin (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Efavirenz (Compound)
Gemtuzumab ozogamicin may cause a minor interaction that can limit clinical effects when taken with Gatifloxacin and Gatifloxacin (Compound) upregulates IKBKB (Gene) and IKBKB (Gene) is upregulated by Efavirenz (Compound)
Gemtuzumab ozogamicin may cause a minor interaction that can limit clinical effects when taken with Gatifloxacin and Gatifloxacin (Compound) downregulates OXA1L (Gene) and OXA1L (Gene) is downregulated by Efavirenz (Compound)
Gemtuzumab ozogamicin may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Efavirenz (Compound)
Gemtuzumab ozogamicin may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin (Compound) upregulates IKBKB (Gene) and IKBKB (Gene) is upregulated by Efavirenz (Compound)
Gemtuzumab ozogamicin may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan (Compound) downregulates OXA1L (Gene) and OXA1L (Gene) is downregulated by Efavirenz (Compound)
Gemtuzumab ozogamicin may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir and Ganciclovir (Compound) causes Creatinine increased (Side Effect) and Creatinine increased (Side Effect) is caused by Efavirenz (Compound)
Gemtuzumab ozogamicin may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate (Compound) upregulates OXA1L (Gene) and OXA1L (Gene) is downregulated by Efavirenz (Compound)
Gemtuzumab ozogamicin may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine and Zidovudine (Compound) treats acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) is treated by Efavirenz (Compound)